Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2− Breast Cancer Based on a Window of Opportunity Study
Alberto D’Angelo(University of Bath), Daniele Generali(University of Trieste), Fabiola Giudici(University of Padua), Jacob Darlow(University of Bath), Maria Rosa Cappelletti(University of Trieste), Huseyin Kilili(University of Bath), Carla Strina(Istituti Ospitalieri di Cremona), Robert Chapman(Princess Alexandra Hospital NHS Trust), Mattia Cinelli(University of Bath), Manuela Milani(Humanitas University), Navid Sobhani(University of Trieste)
Cited by 2
Related Papers
The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib
|Cancer Research|2009|298
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268
Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer
|Clinical Cancer Research|2006|244
Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability
|Cancer Research|2010|205